Halofuginone is an investigational drug.
There have been 5 clinical trials for Halofuginone.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2013.
The most common disease conditions in clinical trials are Muscular Dystrophy, Duchenne, Muscular Dystrophies, and Sarcoma, Kaposi. The leading clinical trial sponsors are Akashi Therapeutics, Processa Pharmaceuticals, and European Organisation for Research and Treatment of Cancer - EORTC.
There are six hundred and fifty-five US patents protecting this investigational drug and nine international patents.